(Reuters) -Kenvue missed Wall Street estimates for third-quarter sales on Monday, while it also announced its acquisition by Kimberly-Clark for about $48.7 billion. The consumer health company's shares rose about 20% in premarket trading following the deal. Kenvue has endured several challenges since its spinoff from Johnson & Johnson in 2023, and was especially scrutinized following President Donald Trump's comments linking its popular pain medicine Tylenol to autism. Last week, U.S. Health and Human S ...